US 11,753,378 B2
Ketamine compounds and processes for making and using them
Guochen Chi, Coralville, IA (US); Sven Guenther, Coralville, IA (US); Travis Mickle, Kissimmee, FL (US); and Adam Smith, Orlando, FL (US)
Assigned to Zevra Therapeutics, Inc., Celebration, FL (US)
Filed by Zevra Therapeutics, Inc., Celebration, FL (US)
Filed on Apr. 18, 2022, as Appl. No. 17/723,189.
Claims priority of provisional application 63/176,499, filed on Apr. 19, 2021.
Prior Publication US 2022/0348544 A1, Nov. 3, 2022
Int. Cl. C07D 213/79 (2006.01); C07D 401/12 (2006.01); C07F 9/10 (2006.01); C07D 265/30 (2006.01); C07D 213/80 (2006.01)
CPC C07D 213/79 (2013.01) [C07D 213/80 (2013.01); C07D 265/30 (2013.01); C07D 401/12 (2013.01); C07F 9/10 (2013.01)] 33 Claims
 
1. A compound having a structure of Formula III, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein L is alkyl;
wherein Z is selected from hydrogen,

OG Complex Work Unit Chemistry
and wherein R4, R5, and R6 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, aryl, substituted aryl, and cycloalkyl.